Nanobiotix S.A. (NBTX)
NBTX trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 20-F (ifrs-full:Revenue), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1760854/000176085426000003/0001760854-26-000003-index.htm. Net income: SEC 20-F (ifrs-full:ProfitLossAttributableToOwnersOfParent), fiscal year ended 2025-12-31. Converted from EUR at 0.9048 per USD (today's ECB or Federal Reserve reference rate).
Profile
| Field | Value |
|---|---|
| Ticker | NBTX on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | France |
| IPO year | 2020 |
| SEC CIK | 0001760854 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | France |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $36.0M |
| Net income | -$26.5M |
| Operating income | -$12.0M |
| Net margin | -73.5% |
| Operating margin | -33.2% |
| Revenue growth | No prior-year revenue to compare |
| Cash | $58.3M |
| Total assets | $74.9M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 40.3× |
Reported in EUR; shown in US dollars.
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. "Accordingly, Management has determined there is no substantial doubt regarding the Company's ability to continue as a going concern." | 20-F 2026-03-31 |
| Cash and burn | 52.8M EUR cash; operating cash flow -8.4M EUR a quarter. | Report 2025-12-31 |
| Shares outstanding | 48,410,068 (2025-12-31); 47,426,851 a year earlier; 34,875,872 three years earlier. the newest SEC cover-page count is from 2025-12-31; shares issued since then are not in these figures. | Cover page 2025-12-31 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 2 424B5 takedowns, 2 at the market | Latest 2026-05-22 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | KPMG SA, Paris La Défense, France | PCAOB Form AP 2026-05-04 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Annual results
| Fiscal year | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| FY 2025 2025-12-31 | 32.6M EUR | -24.0M EUR | -33.4M EUR | 52.8M EUR | No debt tags | 32.6M EUR | 20-F 2026-03-31 |
| FY 2024 2024-12-31 | -7.2M EUR | -68.1M EUR | -19.6M EUR | 49.7M EUR | No debt tags | -7.2M EUR | 20-F 2026-03-31 |
| FY 2023 2023-12-31 | 36.2M EUR | -39.7M EUR | -12.5M EUR | 75.3M EUR | No debt tags | 36.2M EUR | 20-F 2026-03-31 |
| FY 2022 2022-12-31 | 4.8M EUR | -57.0M EUR | -37.1M EUR | 41.4M EUR | No debt tags | 4.8M EUR | 20-F 2025-04-02 |
| FY 2021 2021-12-31 | 2.6M EUR | -47.1M EUR | -29.9M EUR | 83.9M EUR | No debt tags | 2.6M EUR | 20-F 2024-04-24 |
| FY 2020 2020-12-31 | 2.5M EUR | -33.6M EUR | -27.5M EUR | 119.2M EUR | No debt tags | 2.5M EUR | 20-F 2023-04-24 |
| FY 2019 2019-12-31 | 2.5M EUR | -50.9M EUR | -41.2M EUR | 35.1M EUR | No debt tags | 2.5M EUR | 20-F 2022-04-08 |
| FY 2018 2018-12-31 | 3.5M EUR | -30.3M EUR | -26.0M EUR | 36.2M EUR | No debt tags | 3.5M EUR | 20-F/A 2021-04-08 |
From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months). Amounts in EUR.
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-05-22 |
| Latest annual report | 20-F | 2026-03-31 |
| Latest quarterly / interim FORM 6-K | 6-K | 2026-11-12 |
Source: SEC EDGAR submissions feed, 313 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +0.1% |
| 1 month | +42.6% |
| 3 months | -19.7% |
| Year to date | +32.6% |
| 1 year | +51.2% |
| From 52-week high | -44.3% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| PCRX | Pacira BioSciences Inc. | $36.48 | +0.05% | $1.5B |
| RAPP | Rapport Therapeutics Inc. | $24.82 | -5.09% | $1.5B |
| PAHC | Phibro Animal Health Corporation | $35.02 | -2.64% | $1.4B |
| KRSA | Korsana Biosciences Inc. | $32.68 | +3.25% | $1.5B |
| DMRA | Damora Therapeutics Inc. | $22.50 | +4.14% | $1.4B |
| LBRX | LB Pharmaceuticals Inc | $42.99 | -0.05% | $1.4B |
| SLS | SELLAS Life Sciences Group Inc. | $7.47 | -4.96% | $1.5B |
| URGN | UroGen Pharma Ltd. | $28.10 | +7.33% | $1.4B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier